Academic ownership of intellectual property facilitated wide dissemination and commercialization of antibody technology. Moves at the University of Cambridge to reclaim institutional IP rights should thus be treated with caution.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Kohler, G. & Milstein, C. Nature 256, 495–497 (1975).
Milstein, C. Immunol. Today 21, 359–364 (2000).
Hale, G. & Waldmann, H. Methods Mol. Med. 40, 243–266 (2000).
Cambridge University. Third Joint Report of the Council and the General Board on the Ownership of Intellectual Property Rights (IPRs): Notice. Cambridge University Reporter, 6008, 3. (Cambridge University, UK, 2005).
Lambert, R. Lambert Review of Business-University Collaboration (Her Majesty's Stationary Office, Norwich, UK, 2003). http://www.hm-treasury.gov.uk./media/DDE/65/lambert_review_final_450.pdf
Author information
Authors and Affiliations
Author notes
Although he continues to work as an academic research scientist, he is the coinventor of a number of international patents and applications, and has royalty interests in several commercial products, including alemtuzumab (Campath).
Rights and permissions
About this article
Cite this article
Clark, M. Empowering the inventor—the case of monoclonal antibodies. Nat Biotechnol 23, 1047–1049 (2005). https://doi.org/10.1038/nbt0905-1047
Issue Date:
DOI: https://doi.org/10.1038/nbt0905-1047
